Postpartal recurrent non-ST elevation myocardial infarction in essential thrombocythaemia: case report and review of the literature by Spyridon Arampatzis et al.
Arampatzis et al. Thrombosis Journal 2010, 8:12
http://www.thrombosisjournal.com/content/8/1/12
Open AccessC A S E  R E P O R TCase reportPostpartal recurrent non-ST elevation myocardial 
infarction in essential thrombocythaemia: case 
report and review of the literature
Spyridon Arampatzis*1,2, Ioannis Stefanidis2, Vassilios Liakopoulos2, Luigi Raio3, Daniel Surbek3 and 
Markus G Mohaupt1
Abstract
Normal pregnancy corresponds to a procoagulant state. Acute myocardial infarction during pregnancy is rare, yet 
considering the low non-pregnant risk score of childbearing women it is still surprisingly frequent. We report a case of 
postpartum recurrent non-ST elevation myocardial infarction in a 40-year-old caucasian woman with essential 
thrombocythaemia in the presence of a positive JAK-2 mutation and an elevated anti-cardiolipin IgM antibody titer. In 
the majority of cases of myocardial infarction in pregnancy or in the peripartal period, atherosclerosis, a thrombus or 
coronary artery dissection is observed. The combination of essential thrombocythaemia and elevated anti-cardiolipin 
IgM antibody titer in the presence of several cardiovascular risk factors seems to be causative in our case. In conclusion, 
with the continuing trend of childbearing at older ages, rare or unlikely conditions leading to severe events such as 
myocardial infarction must be considered in pregnant women.
Introduction
Essential thrombocythaemia (ET) is a chronic myelopro-
liferative disorder characterized by a sustained elevated
platelet count with a tendency to both thrombosis and
hemorrhage [1,2]. In ET the median age of presentation is
60 years with female predominance [3] and has a favor-
able outcome [4]. A small subset of patients is being diag-
nosed at an earlier age [5,6]. Young women with ET
constitute a special group due to their anticipated long
survival and childbearing potential [7-9]. Pregnancies in
ET patients are likely to be complicated, primarily due to
first trimester spontaneous abortions but for those car-
ried to term, obstetric or thrombohemorrhagic complica-
tions are rare [10].
Pregnancy is an acquired risk factor for thromboembo-
lism associated with increased coagulation and decreased
fibrinolysis [11]. Hemodynamic and hormonal alterations
during pregnancy may further potentiate the risk of vas-
cular events [12,13]. Although rare, acute myocardial
infarction does complicate pregnancy and is estimated to
occur in about 6 per 100,000 women during the peripar-
tal period [14].
Pregnancy-related complications in patients with ET
remains a challenge as platelet count has not been shown
to represent a risk factor for pregnancy complications,
nor the use of aspirin has been demonstrated to influence
pregnancy outcome [9]. We describe a case involving
recurrent non-ST elevation myocardial infarction in the
immediate postpartum period in a young woman with
ET. We review the current literature for pregnancy-
related risk factors of myocardial infarction with respect
to ET.
Case report
A 40-year-old caucasian woman, gravida 3 para 2, devel-
oped postpartal arterial hypertension. Her first preg-
nancy, three years earlier, had been complicated by an
early spontaneous abortion at gestational week 7. In the
following pregnancy, one year later, while on prophylactic
low-molecular weight heparin due to the previous mis-
carriage, a cesarean section was performed at gestational
week 32 due to intrauterine fetal growth restriction
(IUGR), infant birthweight 810 g, 1-, 5-, and 10-min
Apgar scores of 7, 9 and 10, respectively; umbilical cord
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low-dose aspirin was given from gestational week 13 to
week 37 due to IUGR in the former pregnancy. Shortly
after an uneventful elective cesarean section performed
in the 39th week (infant birthweight 2520 g, 1-, 5-, and 10-
min Apgar scores of 9, 9 and 10, respectively; umbilical
cord arterial blood pH: 7.29) monotherapy with 50 mg
metoprolol was started due to postpartal hypertension.
The patient had the same partner since the first preg-
nancy and no history of spontaneous bleeding, thrombo-
sis nor had she been diagnosed to have elevated platelet
counts requiring treatment. During the present preg-
nancy platelet counts were initially elevated but continu-
ously decreased from 598 G/L to 346 G/L at the time of
caesarean delivery.
Risk factors for coronary heart or thromboembolic dis-
eases, including smoking, hyperlipidemia, diabetes melli-
tus or atrial fibrillation were absent except for a positive
family history of coronary artery disease and overweight
(body mass index: 28.6 kg/m2). No medication or illicit
drugs were taken. The patient was breastfeeding.
Three weeks after delivery, she complained of shortness
of breath and acute retrosternal pain accompanied by
severe migraine and arterial hypertension. Despite 10 mg
nifedipin intake, hypertension and retrosternal pain per-
sisted and the patient was referred to a cardiologist with a
supine blood pressure of 180/85 mm Hg and a regular
heart rate at 90 bpm. The clinical examination was other-
wise normal. Her initial ECG revealed a myocardial
injury pattern compatible with a non-significant ST-ele-
vation of the inferior leads.
Laboratory studies (Table 1) showed an elevated plate-
let count (708 G/L) and increased troponin-T levels. A
chest x-ray and a spiral computer tomography angiogra-
phy scan rule out pulmonary thromboembolism. Given
the severe recurrent migraine episodes, a stroke was
excluded by a cerebral computer tomography scan.
During the night, creatinine kinase rose as did tro-
ponin-T (187 to 280 U/l and 0.129 to 0.319 ng/ml, respec-
tively). With the clinical and laboratory findings
suggesting anterior wall myocardial infarction, the
patient was started on aspirin, intravenous heparin and
nitroglycerin, and a coronary angiography was performed
(Fig. 1). This revealed a non-significant plaque in the
proximal left anterior descending (LAD) area of an other-
wise normal coronary artery tree. She was started on
amlodipin, metoprolol, simvastatin, aspirin, and clopi-
dogrel, and the chest pain resolved. The further in-hospi-
tal course was uneventful and 7 days after the coronary
angiography the patient was discharged on aspirin, low
molecular weight heparin, a statin, metoprolol and amlo-
dipin, with an appointment, 5 weeks later, for a further
hematology workup due to the elevated platelet count
and potential additive procoagulatory risk factors.
After 4 weeks the patient was readmitted to the emer-
gency unit complaining of severe chest pain radiating to
the neck. She reported having stopped aspirin as well as
metoprolol and amlodipin 10 days earlier. The clinical
examination revealed a blood pressure of 150/90 mmHg
and a heart rate of 62 bpm. The ECG displayed a regular
rhythm, yet inferior lead non-significant ST-segment ele-
vations. The troponin-T levels were elevated (Table 1)
and echocardiography confirmed a slight anterior wall
hypokinesia already observed during the first ischemic
episode. Medication was restarted and the second coro-
nary angiography showed a hemodynamically non-rele-
vant plaque (10-30%) within the distal branch of the LAD,
with no further new findings (Fig. 1). At this time, para-
doxical embolism and myocardial inflammatory disease
was ruled out by transesophageal echocardiography and
by cardiac nuclear magnetic resonance scan, respectively.
Further hematological work-up confirmed the diagno-
sis of ET by a persistent elevated platelet count, a positive
JAK-2 (V617F)-mutation, a matching bone marrow find-
ing without evidence for iron deficiency or infection.
Potential hereditary risk factors for thrombophilia (factor
V Leiden, prothrombin gene mutations, methylenetetra-
hydrofolate reductase (MTHFR), factor XIII, and PAI-1)
were excluded. Cytogenetics for BCR-ABL, t(9;22), were
negative. IgM anticardiolipin antibodies were transiently
elevated and ANA was 1:160 with negative anti-dsDNA
and anti-Histone antibodies.
Oral hydroxyurea was added to aspirin, but had to be
discontinued due to severe alopecia. In response to alter-
nate treatment with low dose peg-interferon α-2a, plate-
let count normalized. At the one-year follow-up, the
patient presented with normal blood pressure and
remained in remission for hematological and cardiac dis-
ease while remaining on aspirin.
Discussion
Pregnancy is not commonly considered a risk factor for
acute myocardial infarction, however pregnancy increase
the risk of acute myocardial infarction 3- to 4-fold
[14,15]. Many risk factors are unique for pregnancy-
related acute myocardial infarction and several diagnostic
steps are often required for the myocardial infarction
confirmation (Appendix 1).
Cardiac function and hormonal milieu are unfavorably
altered in pregnancy whereas cardiac output is increased
in the presence of elevated levels of estrogen and proges-
terone [12,13]. The hypercoagulable state of pregnancy
[11], in the presence of increased vascular reactivity [16],
may further magnify the risk of myocardial infarction.
Progesterone excess and postpartal degeneration of the
matrix in the medial and intimal sections of the coronary
arteries may contribute to flow alterations and artery dis-
sections [17].
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may further damage blood vessels already weakened by
hemodynamic stress and hormonal alterations. Overall,
an increasing prevalence of cardiovascular risk factors
with advanced maternal age contributes to pregnancy-
associated complications [18,19]. More than 70% of
patients with ET and recurrent thrombosis have multiple
cardiovascular risk factors [20,21]. Overweight, arterial
hypertension and a positive family history were present
in this case, yet all were moderate and hypertension only
recently developed.
In a recent retrospective review of 228 reported cases
of pregnancy-related acute myocardial infarction, mor-
phology of the coronary arteries was present in 164 cases.
Atherosclerosis with or without intracoronary thrombus
was found in 70 cases (43%), and definite or probable cor-
onary thrombus without evidence of atherosclerotic dis-
ease was present in 22 (13%). Coronary artery dissection
was verified in 24%, spasms and embolus in 2% and 1%
respectively. Normal coronary arteries were found in 20%
[16,22]
Published studies on ET pregnancies report live birth
rates of 50-70% and spontaneous abortion rates of 25-
50% [23,24]. In a recent report of 103 pregnancies that
occurred in 62 women with ET, about 50% of first preg-
nancies experienced complications, although no case of
acute coronary syndrome (ACS) or myocardial infarction
was reported during pregnancy or postpartum [9].
Despite the fact that a decrease in platelet count during
pregnancies is well documented, pregnancies in ET
patients frequently end in early spontaneous abortions,
during the first trimester [25]. Their occurrence cannot
be predicted from the disease course, platelet count, or a
specific therapy. The use of aspirin did not improve preg-
nancy outcome in a study of 34 patients with ET by Tef-
feri and coworkers [7,10]. In addition control of the
Table 1: Laboratory parameters at acute coronary syndromes (ACS) episodes
1st episode ACS 2nd episode ACS Values Normal range
Hb 137 139 g/L 121-154
Hct 40 42 % 36-44
Lc 8.6 8.0 G/L 3.5-10.5
Tc 708 559 G/L 140-380
CK max 280 196 U/L <170





IgM anticardiolipin 13.1 MPL-U/mL <5
IgG anticardiolipin 3 GPL-U/mL <10
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surrogate end point to judge the efficacy of a treatment
for ET [26]. In a randomized study comparing anagrelide
vs. hydroxyurea therapy (plus low-dose aspirin in both
groups) in ET [23], an excess of vascular events was found
in the anagrelide group despite a reduction in the platelet
count similar to that in the hydroxyurea group. If the
platelet count decreases insufficiently in patients with ET
despite pregnancy, interferon is considered the agent of
choice, omitting the teratogenicity of cytoreductive
agents [7,27].
Our patient's history of previous early spontaneous
abortion, IUGR and the presence of anticardiolipin anti-
bodies suggest the possibility of an incomplete antiphos-
pholipid antibody syndrome, which represent the most
common acquired thrombophilia of pregnancy and has
been associated with myocardial infarction [28,29].
Antiphospholipid antibody syndromes may also be
associated with autoimmune diseases such as systemic
lupus erythematosus, which can cause pericarditis and
myocarditis [30]. In the present case, autoantibody
screening for ANA was borderline and anti-dsDNA and
anti-Histone antibody testing were negative. A nuclear
magnetic resonance examination of the heart demon-
strated a normal myocardium with no signs of inflamma-
tion.
Our patient had experienced a severe migraine attack
which has also been found to be a risk factor for myocar-
dial infarction during pregnancy [14]. The possible
underlying mechanism may be a generalized vasospasm
that makes coronary arteries susceptible to spasms [31].
Despite the fact that ET-pregnancies carried to term
are rarely complicated by thrombohemorrhagic events
our patient had experienced recurrent postpartal ACS in
the presence of essential thrombocytosis and elevated
antio-cardiolipin IgM antibodies. Since patients with ET
seems to have an increased prevalence of antiphospho-
lipid antibodies which may be associated with thrombosis
[32] it is not surprising that both episodes of ACS
occurred after aspirin discontinuation. We can only spec-
ulate that the conjunction of primary etiological factors
such as ET and the transiently elevated antiphospholipid
antibody titer in the presence of several cardiovascular
risk factors (advanced maternal age, hypertension, post-
partal vascular changes, coronary plaque) and the lack of
antiplatelet therapy finally contributed to recurrent myo-
cardial ischemia.
There are several recommendations [33] that women
whose pregnancies are characterized by fetal complica-
tions, such as unexplained fetal growth retardation and
stillbirth, should be tested for genetic or acquired mark-
ers of thrombophilia as well as antiphospholipid antibod-
ies and autoimmune disease. We propose that, with the
continuing trend of childbearing at older ages, maternal
complications like the ones described here should be
added to the conditions requiring a similar work-up to
allow for closer monitoring, or even prophylactic therapy
during further pregnancies and beyond.
Figure 1 The LAD lesion visible at the first and the second coronary angiography are depicted on the left and right hand side, respectively, 
and indicated by arrows.
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infarction; ACS: acute coranary syndrome; LAD: left
anterior descending; MTHFR: methylenetetrahydrofo-
late reductase; CK: creatine kinase.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Appendix
Appendix 1.
Diagnostic approach of suspected acute myocardial
infarction (AMI) in pregnant women
AMI typical clinical symptoms
Symptoms mimicking myocardial ischemia may also be
present during healthy pregnancies
Electrocardiographic changes
ST-segment depression may also be present due induc-
tion of anesthesia for cesarean section and may persist
after elective cesarean section
Cardiac markers
Troponin I levels: is the most sensitive marker for AMI.
The majority of healthy pregnant women remain below
the upper limit of normal Troponin I levels after delivery.
Creatine kinase/CK-MB: can be significantly elevated
up to 24 h after delivery in healthy pregnant women
Echocardiogram/Stress echocardiography
Safe and accurate for evaluating wall-motion abnormali-
ties
Exercise testing
Submaximal protocol evaluation (70% of maximal pre-
dicted heart rate) with fetal monitoring for the diagnosis
of myocardial ischemia or risk stratification following
AMI
Radionuclide imaging and cardiac MRI
Both modalities may add further information with overall
small or none fetal exposure to radiation
Cardiac catheterization
Possible increased risk of coronary dissection and great
risk of fetal exposure to radiation
Both the cardiologist and obstetrician should establish
the treatment plan
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